The Egg-Based Expression System is an innovative and highly efficient platform for recombinant protein production, utilizing fertilized hen eggs as natural bioreactors. This system provides a rapid, scalable, and cost-effective alternative to conventional expression systems such as bacterial, yeast, insect, and mammalian cells.
By leveraging the eukaryotic microenvironment of developing eggs, this platform enables proper protein folding and post-translational modifications, making it particularly suitable for producing complex, high-value biologics such as vaccines, virus-like particles (VLPs), viral glycoproteins, cytokines, and antibodies.
At Profacgen, we offer a fully integrated Egg-Based Expression service, covering construct design, rapid expression, and purification. With turnaround times as short as 72 hours, our platform is ideal for fast screening, high-throughput protein variant production, and challenging targets that are difficult to express in traditional systems.
Recombinant protein production is fundamental to modern biotechnology, supporting applications ranging from basic research to therapeutic development. Conventional expression systems—including E. coli, yeast, insect cells, and mammalian cells—each offer distinct advantages but also present inherent limitations:
As demand grows for complex, structurally accurate, and functional proteins, alternative platforms are increasingly required to overcome these limitations. Fertilized hen eggs provide a naturally optimized system for protein synthesis and secretion. During embryonic development, the egg supports complex biological processes, including protein folding, secretion, and modification, within a controlled and sterile environment. Recombinant proteins introduced into this system can be expressed and secreted into the allantoic fluid, which serves as a convenient and relatively clean source for downstream purification.
One of the most distinctive features of this system is that each egg functions as an independent micro-bioreactor. This enables parallel processing of multiple constructs without cross-contamination, making it particularly suitable for high-throughput applications such as variant screening and optimization studies. Additionally, the system is inherently scalable: production can be increased simply by increasing the number of eggs, without the need for complex bioreactor infrastructure.
The Egg-Based Expression System has demonstrated strong performance in the production of structurally complex and biologically sensitive proteins. These include viral envelope proteins that require precise folding, cytokines that depend on proper secretion and activity, and antibody fragments that benefit from eukaryotic expression environments. As such, the platform is increasingly recognized as a valuable complement to traditional expression technologies.
Figurer 1. Schematic diagram of egg-based expression system.
Profacgen provides a fully integrated Egg-Based Expression service designed to deliver high-quality recombinant proteins efficiently and reliably. Our workflow encompasses every stage of the production process, from initial construct design to final protein purification and validation.
Construct Design and Molecular Engineering
We tailor each construct for egg-based expression success. Services include codon optimization for enhanced translation, signal peptide selection to promote allantoic fluid secretion, and fusion tag design for purification. We also support protein engineering projects with multiple variants, including site-directed mutants and domain truncations.
Expression in Fertilized Eggs
Constructs are introduced into fertilized hen eggs under controlled conditions. Following incubation, recombinant proteins are secreted into and harvested from the allantoic fluid. This system offers speed and flexibility, with production typically achieved within approximately 72 hours, and supports parallel processing of multiple constructs for efficient screening.
High-Throughput Expression and Screening
Each egg serves as an independent expression unit, enabling high-throughput experimentation. This allows parallel testing of multiple constructs for applications such as screening variants for improved activity, evaluating mutation effects, and comparing construct designs, significantly accelerating R&D.
Protein Harvesting and Purification
Recombinant proteins are harvested from allantoic fluid, which contains low host cell contaminants. We offer flexible purification options from partially purified preparations for screening to highly purified products (up to ≥99%) for functional studies, using affinity and size-exclusion chromatography.
Expression Optimization and Scale-Up
We provide comprehensive optimization services, including adjustments to construct design and expression conditions, to maximize yield and quality. Scale-up is achieved by simply expanding the number of eggs, offering a cost-effective route to milligram-scale production for preclinical research.
Application-Oriented Development Support
Our platform is well-suited for producing viral glycoproteins and VLPs for vaccine research, as well as cytokines and antibodies requiring proper folding. It also offers an effective alternative for expressing proteins that have been challenging in other systems.
Client Requirements:
A research group required a viral glycoprotein for structural and immunological analysis within a tight timeline. Traditional mammalian and insect cell expression systems proved too slow to meet their project deadlines.
Our Solution:
Profacgen applied the Egg-Based Expression platform to produce the target protein in fertilized hen eggs. We optimized construct design with appropriate signal peptides to promote efficient secretion into allantoic fluid. Following incubation, the protein was harvested and purified using streamlined workflows compatible with the allantoic fluid matrix.
Final Results:
Within approximately 72 hours, functional viral glycoprotein was obtained at sufficient yield for downstream structural and immunological studies. The rapid turnaround enabled the client to proceed with characterization without delay, significantly accelerating their research progress and meeting all project milestones.
Client Requirements:
A client sought to identify the most active variant among a panel of engineered therapeutic proteins. Using conventional sequential expression systems, this process would have required months of work and delayed candidate selection.
Our Solution:
Profacgen leveraged the parallel nature of the Egg-Based Expression System, expressing each variant simultaneously in separate eggs under identical conditions. This approach enabled direct, side-by-side comparison of expression levels, stability, and functional activity without batch-to-batch variability.
Final Results:
The optimal protein candidate was rapidly identified within days rather than months, significantly reducing development time and experimental complexity. The client advanced the lead variant into preclinical studies with confidence, benefiting from accelerated timelines and reduced costs.
Consult Our Experts on Your Project
References:
Fill out this form and one of our experts will respond to you within one business day.